Clinical Trial

Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

Study acronym: IVAS
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2016-03-08; most recent amendment 2025-02-24.
Trial Details
NCT Number NCT02706704
Lead Sponsor American University of Beirut Medical Center
Conditions Uveitis, Non-Infectious Uveitis
Enrollment 32 participants
Start Date 2016-02
Primary Completion 2025-12 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-02-26